How many insider trades does FilingIQ track for KRRO?

FilingIQ tracks 75 Form 4 insider transactions for KRRO (Korro Bio, Inc.), covering filings from Nov 3, 2023 onwards. 21 of those were filed in the last 90 days.

Are KRRO insiders net buyers or net sellers?

Across the full Form 4 history for KRRO, 29 transactions (39%) were open-market purchases and 23 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KRRO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KRRO in?

Korro Bio, Inc. (KRRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $149.99M.

KRRO insider trading

NasdaqCM Healthcare

Korro Bio, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

39% / 31%

Market cap

$149.99M

About Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Company website: www.korrobio.com

KRRO insider activity at a glance

FilingIQ has scored 75 insider transactions for KRRO since Nov 3, 2023. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 29 open-market purchases and 23 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KRRO insider trades is 51.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KRRO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading KRRO

Makhzoumi Mohamad

56 trades · score 71.0

13F funds holding KRRO

Artal Group S.A.

$37.73M · 1.0% of AUM

Frequently asked

How many insider trades does FilingIQ track for KRRO?: FilingIQ tracks 75 Form 4 insider transactions for KRRO (Korro Bio, Inc.), covering filings from Nov 3, 2023 onwards. 21 of those were filed in the last 90 days.
Are KRRO insiders net buyers or net sellers?: Across the full Form 4 history for KRRO, 29 transactions (39%) were open-market purchases and 23 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KRRO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KRRO in?: Korro Bio, Inc. (KRRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $149.99M.

Methodology & sources

Every KRRO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.